Augustine Therapeutics is a Belgian biotech company founded in 2019 and a spin-off of VIB-KU Leuven. The company is developing a wide portfolio of best-in-class, novel, potent and subtype-selective small-molecule inhibitors of the enzyme HDAC6 (Histone DeACetylase 6) for the treatment of neurodegenerative and cardiometabolic diseases.
The inhibition of HDAC6 plays a crucial role in axonal protection and regeneration by controlling internal axonal transport. Augustine’s novel and chemically distinct generation of HDAC6 inhibitors, therefore, presents an intriguing approach for selectively reversing and inhibiting the pathophysiological changes associated with neuromuscular diseases such as Charcot-Marie-Tooth (CMT), peripheral induced by chemotherapies (CIPN), as well as neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). Additionally, recent developments outside neurology suggest a relevant role for HDAC6 inhibition in cardiovascular indications and obesity, expanding the potential applications of Augustine’s portfolio.
The current focus of the company is to advance its lead program into clinical development and continue with the pre-clinical development of the rest of its programs.
The inhibition of HDAC6 plays a crucial role in axonal protection and regeneration by controlling internal axonal transport. Augustine’s novel and chemically distinct generation of HDAC6 inhibitors, therefore, presents an intriguing approach for selectively reversing and inhibiting the pathophysiological changes associated with neuromuscular diseases such as Charcot-Marie-Tooth (CMT), peripheral induced by chemotherapies (CIPN), as well as neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). Additionally, recent developments outside neurology suggest a relevant role for HDAC6 inhibition in cardiovascular indications and obesity, expanding the potential applications of Augustine’s portfolio.
The current focus of the company is to advance its lead program into clinical development and continue with the pre-clinical development of the rest of its programs.
Location: Belgium, East Flanders, Ghent
Employees: 1-10
Total raised: $18.15M
Founded date: 2019
Investors 3
| Date | Name | Website |
| - | V-Bio Vent... | v-bio.vent... |
| 09.07.2024 | Asabys Par... | asabys.com... |
| - | KU Leuven ... | lrd.kuleuv... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.06.2024 | Series A | $18.15M | - |
Mentions in press and media 4
| Date | Title | Description |
| 26.06.2024 | Augustine Therapeutics Raises EUR 17M in Series A First Closing | Augustine Therapeutics, a Leuven, Belgium-based biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, raised EUR 17M in its first closing of Series A funding. The round was led by Asabys Partners, w... |
| 02.03.2023 | CMT Research Foundation (USA) collaborates with Augustine on new therapy against Charcot-Marie-Tooth disease | Augustine Therapeutics Logo LEUVEN, BELGIUM, March 2, 2023 /EINPresswire.com/ -- Augustine Therapeutics announces a collaboration with the Charcot-Marie-Tooth Research Foundation (CMTRF) in the USA. CMTRF is a US-based, patient-led, non-pro... |
| 10.05.2022 | Augustine Therapeutics appoints Gerhard Koenig as Chairman of the Board, forms Clinical Advisory Board | Augustine Therapeutics Logo LEUVEN, BELGIUM, May 10, 2022 /EINPresswire.com/ -- Augustine Therapeutics, a biotech company developing novel therapies for neuromuscular and neurodegenerative disorders, appoints Gerhard Koenig as Chairman of t... |
| - | Augustine Therapeutics | “Augustine, Innovative therapies for neuromuscular and neurodegenerative diseases” |